fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Clopidogrel bisulfate

16 general benefit · 3 not a benefit

Apo-Clopidogrel · DIN 02252767 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Clopidogrel · DIN 02252767 Manufacturer: Apotex Inc.; listing date 2012-01-19 Health Canada: Marketed since 2011-12-19 · brand APO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252767)

Source record
DIN 02252767: Apo-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id APX Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252767 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73770
Interchangeable products
Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: active shortage (reported September 29, 2026, estimated to end October 30, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252767
Shortage record checked October 6, 2026

Auro-Clopidogrel · DIN 02416387 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Clopidogrel · DIN 02416387 Manufacturer: Auro Pharma Inc.; listing date 2014-04-30 Health Canada: Marketed since 2014-02-06 · brand AURO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416387)

Source record
DIN 02416387: Auro-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id AUR Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416387 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90094
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended September 13, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416387
Shortage record checked October 6, 2026

Bio-Clopidogrel · DIN 02444895 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Clopidogrel · DIN 02444895 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2023-08-02 · brand BIO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Bio-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444895)

Source record
DIN 02444895: Bio-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id BMP Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444895 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93012
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02444895
Shortage record checked October 6, 2026

Clopidogrel · DIN 02385813 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clopidogrel · DIN 02385813 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-11 · brand CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02385813)

Source record
DIN 02385813: Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SIV Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02385813 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87143
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended April 9, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385813
Shortage record checked October 6, 2026

Clopidogrel · DIN 02400553 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clopidogrel · DIN 02400553 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2026-09-10 · brand CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02400553)

Source record
DIN 02400553: Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SAI Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02400553 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88535
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended February 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02400553
Shortage record checked October 6, 2026

Jamp-Clopidogrel · DIN 02415550 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Clopidogrel · DIN 02415550 Manufacturer: Jamp Pharma Corporation; listing date 2014-07-30 Health Canada: Marketed since 2014-01-15 · brand JAMP-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02415550)

Source record
DIN 02415550: Jamp-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id JPC Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02415550 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90014
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended August 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415550
Shortage record checked October 6, 2026

M-Clopidogrel · DIN 02502283 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Clopidogrel · DIN 02502283 Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2020-11-03 · brand M-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502283)

Source record
DIN 02502283: M-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id MAT Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502283 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99186
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended February 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502283
Shortage record checked October 6, 2026

Mar-Clopidogrel · DIN 02422255 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Clopidogrel · DIN 02422255 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-06-26 Health Canada: Marketed since 2023-06-14 · brand MAR-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02422255)

Source record
DIN 02422255: Mar-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id MAR Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02422255 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90695
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended April 13, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02422255
Shortage record checked October 6, 2026

Mint-Clopidogrel · DIN 02408910 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Clopidogrel · DIN 02408910 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-09-27 Health Canada: Marketed since 2023-03-29 · brand MINT-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02408910)

Source record
DIN 02408910: Mint-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id MIN Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02408910 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89366
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended April 4, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02408910
Shortage record checked October 6, 2026

NRA-Clopidogrel · DIN 02482037 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Clopidogrel · DIN 02482037 Manufacturer: Nora Pharma; listing date 2020-06-30 Health Canada: Marketed since 2020-03-05 · brand NRA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

NRA-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02482037)

Source record
DIN 02482037: NRA-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id NRA Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482037 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97237
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482037
Shortage record checked October 6, 2026

PMS-Clopidogrel · DIN 02348004 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Clopidogrel · DIN 02348004 Manufacturer: Pharmascience Inc.; listing date 2012-02-29 Health Canada: Marketed since 2011-12-14 · brand PMS-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02348004)

Source record
DIN 02348004: PMS-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id PMS Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02348004 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83336
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended October 1, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02348004
Shortage record checked October 6, 2026

Plavix · DIN 02238682 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: RxHelp ONE lists PLAVIX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Plavix · DIN 02238682 Manufacturer: Sanofi Aventis Pharma; listing date 2003-09-04 Health Canada: Marketed since 2007-04-10 · brand PLAVIX · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238682)

Source record
DIN 02238682: Plavix Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SAV Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $2.9350; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238682 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62114
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended December 11, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238682
Shortage record checked October 6, 2026

Ran-Clopidogrel · DIN 02379813 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Clopidogrel · DIN 02379813 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2012-06-26 Health Canada: Marketed since 2026-09-09 · brand SPC-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02379813)

Source record
DIN 02379813: Ran-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id RAN Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02379813 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86568
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended May 23, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379813
Shortage record checked October 6, 2026

Teva-Clopidogrel · DIN 02293161 · 75 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Clopidogrel · DIN 02293161 Manufacturer: Teva Canada Limited; listing date 2012-02-29 Health Canada: Marketed since 2011-12-14 · brand TEVA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02293161)

Source record
DIN 02293161: Teva-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id TEV Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02293161 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77854
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631
Shortage status: shortage reported ended July 31, 2026 (report last updated July 31, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293161
Shortage record checked October 6, 2026

Apo-Clopidogrel · DIN 02398591 · 300 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Apo-Clopidogrel · DIN 02398591 Manufacturer: Apotex Inc.; listing date 2013-06-27 Health Canada: Marketed since 2013-01-21 · brand APO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02398591)

Source record
DIN 02398591: Apo-Clopidogrel Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000663; group id 906; item number 2169; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.5447; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02398591 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88354
Interchangeable products
Plavix · DIN 02330555 · not recorded Teva-Clopidogrel · DIN 02388065 · not recorded
Shortage status: active shortage (reported September 1, 2026, estimated to end October 30, 2026, last updated September 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02398591
Shortage record checked October 6, 2026

Teva-Clopidogrel · DIN 02388065 · 300 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Teva-Clopidogrel · DIN 02388065 Manufacturer: Teva Canada Limited; listing date 2012-08-27 Health Canada: Marketed since 2013-01-02 · brand TEVA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388065)

Source record
DIN 02388065: Teva-Clopidogrel Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000663; group id 906; item number 2169; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.5447; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388065 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87363
Interchangeable products
Apo-Clopidogrel · DIN 02398591 · not recorded Plavix · DIN 02330555 · not recorded
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388065
Shortage record checked October 6, 2026

Co Clopidogrel · DIN 02303027 · 75 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.Discontinued April 29, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Clopidogrel · DIN 02303027 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19 Health Canada: Cancelled post market since 2025-04-29 · brand ACT CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Co Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02303027)

Source record
DIN 02303027: Co Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id COB Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02303027 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78834
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: discontinued (February 28, 2018, reported by ACTAVIS PHARMA COMPANY); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02303027
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 29, 2025 — choose a marketed DIN from the same-category list.

Sandoz Clopidogrel · DIN 02359316 · 75 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.Discontinued June 28, 2021 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Clopidogrel · DIN 02359316 Manufacturer: Sandoz Canada Inc.; listing date 2012-02-29 Health Canada: Cancelled post market since 2021-06-28 · brand SANDOZ CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Clopidogrel: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2631). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02359316)

Source record
DIN 02359316: Sandoz Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2168; lccId None; manufacturer id SDZ Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02359316 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84434
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended June 28, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02359316
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 28, 2021 — choose a marketed DIN from the same-category list.

Plavix · DIN 02330555 · 300 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.Discontinued December 10, 2020 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Savings card: RxHelp ONE lists PLAVIX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Plavix · DIN 02330555 Manufacturer: Sanofi Aventis Pharma; listing date 2012-08-27 Health Canada: Cancelled post market since 2020-12-10 · brand PLAVIX · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Plavix: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02330555)

Source record
DIN 02330555: Plavix Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000663; group id 906; item number 2169; lccId None; manufacturer id SAV Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02330555 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81628
Interchangeable products
Apo-Clopidogrel · DIN 02398591 · not recorded Teva-Clopidogrel · DIN 02388065 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330555
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 10, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (B01AC): coverage varies; not interchangeable

  • Ticlopidine (Ticlid): limited Use 219, 220, 221, not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

TICLOPIDINE HCL

· 2 products · Listed, not a benefit (1), Limited Use, codes 219, 220, 221 (1) · strengths: 250mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS PLAVIX (clopidogrel bisulfate) is indicated: • for the secondary prevention of atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerosis documented by stroke, myocardial infarction, or established peripheral arterial disease. • in combination with acetylsalicylic acid (ASA), for the early and long-term secondary prevention of atherothrombotic events (myocardial infarction, ischemic stroke, cardiovascular death and/or refractory ischemia) in patients with acute coronary syndromes - without ST segment elevation (i.e., unstable angina or non-Q-wave myocardial infarction). These benefits of PLAVIX have been shown only when these patients were concomitantly treated with ASA in addition to other standard therapies. These benefits were also seen in patients who were managed medically and those who were managed with percutaneous coronary intervention (with or without stent) or CABG (coronary artery bypass graft). • For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of an endpoint of all-cause m… https://pdf.hres.ca/dpd_pm/00067958.PDF PM date: OCT 07, 1998 Source product: PLAVIX; DIN 02238682; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Clopidogrel · DIN 02252767 Shortage status: active shortage (reported 2026-09-29, estimated to end 2026-10-30, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252767

Check this DIN again

Teva-Clopidogrel · DIN 02293161 Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293161

Check this DIN again

Apo-Clopidogrel · DIN 02398591 Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-30, last updated 2026-09-04); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02398591

Check this DIN again

Teva-Clopidogrel · DIN 02388065 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388065

Check this DIN again

Co Clopidogrel · DIN 02303027 Shortage status: discontinued (2018-02-28, reported by ACTAVIS PHARMA COMPANY); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02303027

Check this DIN again

Plavix · DIN 02330555 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330555

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Apo-Clopidogrel, Teva-Clopidogrel, Plavix: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026